Compare LIVE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LIVE | BOLD |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3M | 26.2M |
| IPO Year | N/A | 2024 |
| Metric | LIVE | BOLD |
|---|---|---|
| Price | $14.00 | $1.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 12.2K | ★ 185.6K |
| Earning Date | 12-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.93 | N/A |
| Revenue | ★ $444,944,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $1.00 |
| 52 Week High | $25.88 | $3.45 |
| Indicator | LIVE | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 47.85 |
| Support Level | $9.05 | $1.11 |
| Resistance Level | $17.35 | $1.20 |
| Average True Range (ATR) | 1.55 | 0.07 |
| MACD | 0.77 | 0.01 |
| Stochastic Oscillator | 70.33 | 80.00 |
Live Ventures Inc is a holding company for diversified businesses. It is focused on acquiring and operating profitable companies in various industries. The company operates in the business segments of Retail Entertainment which includes direct sales of entertainment and appliance products and services, Flooring Manufacturing, Steel Manufacturing, which includes the sale of steel plates, ground flat stock, and drill rods, and Corporate and Other. It derives key revenue from the Flooring Manufacturing segment which includes the manufacturing of carpets and rugs, yarn products, as well as a reseller of hard surface flooring products. Geographically the activities are carried out throughout the United States.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.